Status:
COMPLETED
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight® (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine ...
Eligibility Criteria
Inclusion
- Informed consent obtained before any study-related activities. Study-related activities are any procedure related to recording of data according to the protocol
- Male and female patients with the diagnosis of haemophilia A
- Age range is 0 year and above
- A decision to initiate treatment with commercially available NovoEight® has been made by the patient/parent and the physician
Exclusion
- Known or suspected allergy to study product(s) or related products
- Previous participation in this study. Participation is defined as informed consent obtained
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Key Trial Info
Start Date :
August 4 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02207218
Start Date
August 4 2014
End Date
November 10 2020
Last Update
November 15 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Suginami-ku, Tokyo, Japan, 1670035
2
Novo Nordisk Investigational Site
Tokyo, Japan, 167-0035